Relentless Research
We are dedicated to discovering and developing effective treatments to end ALS. We will not stop until there are treatments for every single person living with ALS. Our cutting edge approach has resulted in:
  • The rigorous screening of over 400 potential treatments for ALS—more than any other ALS research lab in the world.
  • The world's first Precision Medicine Program, a partnership with people living with ALS, designed to speed up drug discovery and therapeutic development for ALS.
  • ALS TDI becoming the first nonprofit biotech in any disease to develop a potential treatment, AT-1501, and bring it from our own labs, through FDA review and into clinical trial.
  • The improvement of worldwide standards for preclinical drug screening in models of ALS.
Research Relentless
Our Four Pillars to Discovering
Effective Treatments
1 We Operate
One of the largest preclinical drug validation programs in als.
There are too few potential treatments in clinical trials for ALS. We need a robust, good quality drug pipeline to ultimately treat every person with ALS. More treatments mean more hope.
2 We Validate
More models of als to allow for rigorous testing.
ALS is extremely complex involving a myriad of biological pathways. To test drugs more rigorously, we need a variety of both cell and animal models to capture all of the complexities of ALS.
3 We Aim
To improve how als clinical trials are run.
Clinical trials for ALS currently require too many participants. That slows the studies down and makes them very costly. Using emerging technologies, we hope to make clinical trials more efficient to reveal the most promising treatments faster.
4 We Learn
About ALS from people with ALS.
We believe that best way to learn more about ALS is to partner with people with ALS. Through our Precision Medicine Program, we combine medical histories, family histories, genetics, biomarkers, and patient cell biology to better understand the processes that drive and influence ALS.
Precision Medicine Program
Our Precision Medicine Program (PMP) is the most comprehensive and longest running translational research study in ALS. Through the PMP, our researchers partner with people with ALS to share and gather data to better understand the disease. Our ultimate goals are to discover new treatments for ALS and make clinical trials faster and more efficient. But it only works if you participate.
How We're Targeting ALS
ALS is a complex disease involving many biological pathways; like oxidative stress, immune modulation, unfolded protein response, and more. This means that we have a number of targets to take aim at when testing potential treatments for ALS. At ALS TDI we work on many projects simultaneously to ensure there is a robust pipeline of potential therapies that will ultimately treat every person with ALS.
How We're Targeting ALS
Combined Federal Campaign
Work for the Federal Government? Support ALS
research by joining the Combined Federal Campaign.